Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.43 |
| ▸ | RXRA | P19793 | 11/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649218 | 0.87 | NR1H2 (0.47) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL25705133 | 0.83 | NR1H2 (0.49) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL14937861 | 0.83 | NR1H2 (0.49) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL30686503 | 0.83 | NR1H2 (0.49) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL21172949 | 0.83 | NR1H2 (0.49) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL6641699 | 0.82 | BACE1 (0.43) | BACE1PDK2 | |
| SCHEMBL3735167 | 0.81 | NR1H2 (0.48) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL13563955 | 0.81 | NR1H2 (0.43) | NR1H2RXRANR1H3MAPK1PDK2 | |
| SCHEMBL1195957 | 0.80 | NR1H2 (0.51) | NR1H2RXRANR1H3MAPK1BACE1 | |
| SCHEMBL1195959 | 0.80 | NR1H2 (0.51) | NR1H2RXRANR1H3MAPK1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774132-B1 | Spirooxindole derivatives that act as analgesics | ASTRAZENECA AB (SE) | 2004-08-10 | — | — | US | disclosed |
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | OPRK1, OPRD1, OPRL1 | NR1H2 163/4885RXRA 1231/4885NR1H3 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.